Last week, Johnson & Johnson agreed to pay $158 million to settle a lawsuit filed by the Texas attorney general, who charged the health care giant had orchestrated a controversial program that was designed to boost the use of the Risperdal antipsychotic in the public sector throughout the country (back story). The charges stemmed from a whistleblower lawsuit filed in 2004 by a Pennsylvania state investigator named Allen Jones, who uncovered the program, known as the Texas Medication Algorithm Project. J&J had been accused of surreptitiously creating and funding TMAP, and relied on various state officials and academics to develop and sell the program as a policy tool. Jones was fired for his trouble, but his efforts laid the groundwork for numerous federal and state investigations - J&J has reportedly reached a tentative deal to pay up to $1 billion to settle a federal probe into Risperdal marketing and resolve civil charges, and also agreed to a misdemeanor charge over the same issues. We spoke to Jones, a 57-year-old who divides his time between litigation consulting and stone masonry, about the recent trial and what this has meant…
via pharmalot.com
No comments:
Post a Comment